GILD logo Gilead Sciences +
Gilead Sciences
+

Gilead Sciences (GILD) Business News

Track Gilead Sciences in real time with a live news feed covering Gilead Sciences stock news, official press releases, company announcements, and an archive of historical Gilead Sciences news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
9:21 PM | Thursday | May 14, 2026 Business Wire

Gilead Prices $3 Billion of Senior Unsecured Notes

News Thumbnail
8:30 AM | Wednesday | May 13, 2026 Business Wire

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

News Thumbnail
8:30 AM | Wednesday | May 13, 2026 Business Wire

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

News Thumbnail
4:01 PM | Thursday | May 7, 2026 Business Wire

Gilead Sciences Announces First Quarter Financial Results

News Thumbnail
6:00 AM | Friday | May 1, 2026 Business Wire

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

News Thumbnail
8:30 AM | Wednesday | Apr 29, 2026 Business Wire

U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

News Thumbnail
8:45 AM | Tuesday | Apr 28, 2026 Business Wire

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

News Thumbnail
6:15 PM | Monday | Apr 27, 2026 Business Wire

AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

News Thumbnail
4:05 PM | Wednesday | Apr 22, 2026 Business Wire

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

News Thumbnail
8:30 AM | Friday | Apr 17, 2026 Business Wire

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

News Thumbnail
12:00 PM | Tuesday | Apr 14, 2026 Business Wire

PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access

News Thumbnail
1:01 PM | Friday | Apr 10, 2026 Business Wire

AHF Slams Gilead for Role in Florida AIDS Drug Crisis

News Thumbnail

Gilead Prices $3 Billion of Senior Unsecured Notes

Business Wire

9:21 PM | Thursday | May 14, 2026

news photo
Loading...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.
600% senior notes maturi.

Read full article redirect
9:21 PM | Thursday | May 14, 2026

Gilead Prices $3 Billion of Senior Unsecured Notes

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.
600% senior notes maturi.

Read full article arrow
News Thumbnail
8:30 AM | Wednesday | May 13, 2026

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and long-term study data for Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union.
Analyses fr.

Read full article arrow
News Thumbnail
8:30 AM | Wednesday | May 13, 2026

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and long-term study data for Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union.
Analyses fr.

Read full article arrow
News Thumbnail
4:01 PM | Thursday | May 7, 2026

Gilead Sciences Announces First Quarter Financial Results

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2026. “Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer.
“Building on the strongest pipel.

Read full article arrow
News Thumbnail
6:00 AM | Friday | May 1, 2026

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 12 at 2:20 PM Pacific Time RBC Capital Markets Global Healthcare Conference on Tuesday, May 19 at 11:00 AM Eastern Time Bernstein Annual Strategic Decisions Conference on Thursday, May 28 at 11:00 AM Eastern Time Goldman Sachs Annual Global Healthcare Conference on Tuesday, Ju.

Read full article arrow
News Thumbnail
8:30 AM | Wednesday | Apr 29, 2026

U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) – an investigational, once-daily single-tablet combination regimen for the treatment of HIV in adults who are virologically suppressed.
The FDA has granted priority review of the application and assigned a Prescription Drug User Fee Act (PDUFA) action date of Aug.

Read full article arrow
News Thumbnail
8:45 AM | Tuesday | Apr 28, 2026

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.
8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and.

Read full article arrow
News Thumbnail
6:15 PM | Monday | Apr 27, 2026

AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

Business Wire

LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities.

Read full article arrow
News Thumbnail
4:05 PM | Wednesday | Apr 22, 2026

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2026 financial results and guidance will be released on Thursday, May 7, 2026 after the market closes. At 4:30 p.m.
Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2026 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one ye.

Read full article arrow
News Thumbnail
8:30 AM | Friday | Apr 17, 2026

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. On April 13, 2026, the Australian Competition and Consumer Commission (ACCC) published its decision that the acquisition of Arcellx may be put into effect, subject to expi.

Read full article arrow
News Thumbnail
12:00 PM | Tuesday | Apr 14, 2026

PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #EndHIV--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead's twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028.
Bringing together th.

Read full article arrow
News Thumbnail
1:01 PM | Friday | Apr 10, 2026

AHF Slams Gilead for Role in Florida AIDS Drug Crisis

Business Wire

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #AHFcares--AHF Slams Gilead for Role in Florida AIDS Drug Crisis.

Read full article arrow
News Thumbnail